PF-5212372

DB19212InvestigationalSmall molecule

PF-5212372 is under investigation in clinical trial NCT02795832 (A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis).

Mechanism: Pharmacologically active on Cytosolic phospholipase A2
Curator reviewed
Formula / weight: C₄₂H₃₈ClF₃N₂O₆S₂ · 823.34 g/mol (avg)
Also known as: Benzenepropanoic acid, 4-((2-(5-chloro-1-(diphenylmethyl)-2-(2-((((2-(trifluoromethyl)phenyl)methyl)sulfonyl)amino)ethyl)-1h-indol-3-yl)ethyl)sulfonyl)-
Code names: PF-05212372 · PF-5212372 · PLA-950 · ZPL-521 · ZPL-5212372

Resolves to

Compound

UNII7LNI1E5EFACAS916136-25-9ChEMBLCHEMBL4650312

Structure

InChIKeyHWNIPKHEEVNHMN-UHFFFAOYSA-NSMILESOC(=O)CCC1=CC=C(C=C1)S(=O)(=O)CCC1=C(CCNS(=O)(=O)CC2=CC=CC=C2C(F)(F)F)N(C(C2=CC=CC=C2)C2=CC=CC=C2)C2=CC=C(Cl)C=C12

Targets

P47712PLA2G4A

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with PF-5212372, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account